New York – September 28, 2026 -- Brixmor Property Group Inc. (NYSE: BRX) and Everview Partners have entered definitive agreements to acquire Slate Grocery REIT in a transaction valued at $2.34 billion, splitting the portfolio between a wholly owned Brixmor acquisition and a newly formed joint venture backed by a subsidiary of the Abu Dhabi Investment Authority.

Toronto – September 28, 2026 -- Sixty Degree Capital (SDC) saw five portfolio companies complete initial public offerings in 2026, including the largest IPO in history and the largest biotech IPO on record. SpaceX, Parabilis Medicines, Cerebras, HawkEye 360 and Lime each began trading on U.S. exchanges between May and July, while GrubMarket has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission.

Chicago – September 28, 2026 -- GTCR has closed its acquisition of Tactacam, a cellular-connected camera provider serving more than one million subscribers, buying the company from Bertram Capital and its founders in a deal with undisclosed terms.

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

Calgary, AB – September 28, 2026 -- High Tide Inc. placed No. 315 out of 375 companies on the 2026 Report on Business ranking of Canada's Top Growing Companies, posting a verified three-year revenue growth rate of 66% between 2022 and 2025.

New York – – September 28, 2026 -- Infrastructure Capital Advisors, LLC has increased monthly distributions across four exchange-traded funds, with its newest fund, the Nasdaq Option Income ETF (QVOL), raising its payout by $0.05 to $1.09 per share.

Tokyo – September 28, 2026 -- SOLA Biosciences Japan GK has secured a grant of approximately 6 billion yen over five years from Japan's Agency for Medical Research and Development (AMED) to advance SOL-257, a gene therapy candidate targeting the TDP-43 protein implicated in amyotrophic lateral sclerosis (ALS). The award, granted under AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, was announced June 5, 2026, and positions SOLA Japan as the company's central development hub for the program.

Stockholm – September 28, 2026 -- Telefonaktiebolaget LM Ericsson repurchased Class B shares on Nasdaq Stockholm during the week of September 21-25, 2026, lifting its total treasury stock holding to 108,518,663 Class B shares.

Shanghai – September 26, 2026 -- IASO Biotechnology reported a 90% objective response rate and 90% minimal residual disease (MRD) negativity rate for its BCMA-targeted in vivo CAR-T therapy IASO206, generated via a single intravenous infusion without lymphodepleting chemotherapy, in first-in-human Phase 1 data presented as a late-breaking oral session (LBA-11) at the 2026 International Myeloma Society Annual Meeting.

Whitefish, Mont. – September 25, 2026 -- STEMREGEN, a maker of science-backed stem cell supplements, has landed at No. 332 on the 2026 Inc. 5000 list after posting 1,017% revenue growth over three years, far outpacing the list's 130% median.

Company secures third straight Inc. 5000 ranking as growth trajectory accelerates

STEMREGEN previously ranked No. 265 in 2025 and No. 1,765 in 2024, marking three consecutive years on the annual list of America's fastest-growing private companies. The 2026 ranking measures revenue growth from 2022 through 2025.